180 related articles for article (PubMed ID: 36409537)
1. Ocular Side Effects of Bisphosphonates: A Review of Literature.
Chartrand NA; Lau CK; Parsons MT; Handlon JJ; Ronquillo YC; Hoopes PC; Moshirfar M
J Ocul Pharmacol Ther; 2023; 39(1):3-16. PubMed ID: 36409537
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonate-induced ocular and orbital inflammation].
Jakobsen TS; Funding M
Ugeskr Laeger; 2022 Jul; 184(28):. PubMed ID: 35959811
[TBL] [Abstract][Full Text] [Related]
3. Aminobisphosphonate-associated orbital and ocular inflammatory disease.
Keren S; Leibovitch I; Ben Cnaan R; Neudorfer M; Fogel O; Greenman Y; Shulman S; Zur D; Habot-Wilner Z
Acta Ophthalmol; 2019 Aug; 97(5):e792-e799. PubMed ID: 30816018
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate-associated adverse events.
Papapetrou PD
Hormones (Athens); 2009; 8(2):96-110. PubMed ID: 19570737
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
[TBL] [Abstract][Full Text] [Related]
6. Acute retinal pigment epithelial detachment secondary to pamidronate administration.
Dasanu CA; Alexandrescu DT
J Oncol Pharm Pract; 2009 Jun; 15(2):119-21. PubMed ID: 18818218
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
French DD; Margo CE
Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608
[TBL] [Abstract][Full Text] [Related]
9. New bisphosphonates in the treatment of bone diseases.
Gatti D; Adami S
Drugs Aging; 1999 Oct; 15(4):285-96. PubMed ID: 10582775
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.
Etminan M; Forooghian F; Maberley D
CMAJ; 2012 May; 184(8):E431-4. PubMed ID: 22470169
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
Zhou J; Ma X; Wang T; Zhai S
Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
[TBL] [Abstract][Full Text] [Related]
15. Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Xiao Y; Chen Y; Huang Y; Xiao Y
Sci Rep; 2023 Jul; 13(1):10892. PubMed ID: 37407650
[TBL] [Abstract][Full Text] [Related]
16. Risedronate-associated scleritis: a case report and review of the literature.
Hemmati I; Wade J; Kelsall J
Clin Rheumatol; 2012 Sep; 31(9):1403-5. PubMed ID: 22864810
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
18. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
Tian Y; Wang R; Liu L; Ma C; Lu Q; Yin F
BMC Musculoskelet Disord; 2016 Feb; 17():72. PubMed ID: 26867651
[TBL] [Abstract][Full Text] [Related]
19. Scleritis and other ocular side effects associated with pamidronate disodium.
Fraunfelder FW; Fraunfelder FT; Jensvold B
Am J Ophthalmol; 2003 Feb; 135(2):219-22. PubMed ID: 12566027
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced ocular inflammation.
Samalia P; Sims J; Niederer R
N Z Med J; 2020 Dec; 133(1527):83-94. PubMed ID: 33332330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
